Literature DB >> 12483747

Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease.

Masahiro Iwamoto1, Hiroyuki Nara, Daisuke Hirata, Seiji Minota, Norihiro Nishimoto, Kazuyuki Yoshizaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12483747     DOI： 10.1002/art.10620

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  24 in total

Review 1.  A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature.

Authors:  Katja Perdan-Pirkmajer; Sonja Praprotnik; Matija Tomšič
Journal:  Clin Rheumatol       Date:  2010-08-24       Impact factor: 2.980

Review 2.  Diagnosis and management of adult onset Still's disease.

Authors:  P Efthimiou; P K Paik; L Bielory
Journal:  Ann Rheum Dis       Date:  2005-10-11       Impact factor: 19.103

3.  [Adult onset Still's disease].

Authors:  B Manger
Journal:  Z Rheumatol       Date:  2008-09       Impact factor: 1.372

Review 4.  Successful treatment of adult-onset Still's disease with tocilizumab monotherapy: two case reports and literature review.

Authors:  Ryota Sakai; Hayato Nagasawa; Eiko Nishi; Ayumi Okuyama; Hirofumi Takei; Takahiko Kurasawa; Tsuneo Kondo; Koji Nishimura; Yuichiro Shirai; Tatsuya Ito; Hideto Kameda; Tsutomu Takeuchi; Koichi Amano
Journal:  Clin Rheumatol       Date:  2012-01-04       Impact factor: 2.980

Review 5.  Tocilizumab (Actemra).

Authors:  Martin Sheppard; Faidra Laskou; Philip P Stapleton; Shahryar Hadavi; Bhaskar Dasgupta
Journal:  Hum Vaccin Immunother       Date:  2017-09-02       Impact factor: 3.452

Review 6.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

7.  Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still's disease.

Authors:  Taio Naniwa; Rei Ito; Maiko Watanabe; Yoshihito Hayami; Shinji Maeda; Kaneshige Sasaki; Shiho Iwagaitsu
Journal:  Clin Rheumatol       Date:  2010-09-15       Impact factor: 2.980

Review 8.  Interleukin-6 blockade in ocular inflammatory diseases.

Authors:  M Mesquida; A Leszczynska; V Llorenç; A Adán
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

9.  Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab.

Authors:  Kazuko Matsumoto; Takao Nagashima; Shino Takatori; Yuta Kawahara; Masaki Yagi; Masahiro Iwamoto; Hitoaki Okazaki; Seiji Minota
Journal:  Clin Rheumatol       Date:  2009-01-30       Impact factor: 2.980

10.  Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis.

Authors:  Troels Herlin
Journal:  Core Evid       Date:  2010-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.